Sanofi Diabetes
YOU ARE HERE
Apidra®
For U.S. Healthcare Professionals Only
Help your patients save on Apidra® through our Mealtime Masters Program! Learn more >>
CHANGE TEXT SIZE   Decrease text size Increse text size

co-pay, copay, insulin pens, solostar shortage, apidra solostar shortage, pen shortage, insulin supply
Apidra<sup>®</sup> SoloSTAR<sup>®</sup> temporary supply shortage
US.GLU.13.04.023

The Apidra®
SoloSTAR® Pen.
Discreet on-the-go
dosing. Learn more
about what the pen
can do for you.

LEARN MORE



Mealtime Masters Program
US.GLU.13.04.026

Learn about great
savings and support
for your patients

with the Apidra® No
Co-Pay* Savings Card

Learn more

*Certain exclusions and restrictions apply


a The dose of Apidra® should be given within 15 minutes before or within 20 minutes after starting a meal.

b The dosage of Apidra® should be individualized and determined based on a physician's advice in accordance with the needs of the patient.

Apidra® is a rapid-acting insulin analog indicated to improve glycemic control in adults with type 2 diabetes or adults and children (4 years and older) with type 1 diabetes.

When used as a mealtime insulin, the dose of Apidra® should be given within 15 minutes before or within 20 minutes after starting a meal. Apidra® given by subcutaneous injection should normally be used in regimens that include a longer-acting insulin.

Important Safety Information for Apidra® (insulin glulisine [rDNA origin] injection)

CONTRAINDICATIONS

Apidra® is contraindicated during episodes of hypoglycemia and in patients hypersensitive to Apidra® or any of its excipients.

WARNINGS AND PRECAUTIONS

Closely monitor blood glucose in all patients treated with insulin. Change insulin regimens cautiously and only under medical supervision. Changes in insulin strength, manufacturer, type, or method of administration may result in the need for a change in insulin dose or an adjustment in concomitant oral antidiabetic treatment. As with all insulin preparations, the time course of Apidra® action may vary by individual or at different times in the same individual and is dependent on many conditions, including the site of injection, local blood supply, or local temperature.

Hypoglycemia is the most common adverse reaction of insulin therapy, including Apidra®, which may be serious.

Severe life-threatening, generalized allergy, including anaphylaxis, can occur. All insulins, including Apidra®, can cause hypokalemia, which if untreated, may be serious.

A reduction in the Apidra® dose may be required in patients with renal or hepatic impairment.

Apidra® for subcutaneous injection should not be mixed with insulins other than NPH. Do not mix Apidra® with any insulin when used in the pump or for intravenous administration. Insulin devices and needles must not be shared between patients.

DRUG INTERACTIONS

Certain drugs may affect glucose metabolism, requiring insulin dose adjustment and close monitoring of blood glucose. The signs of hypoglycemia may be reduced in patients taking anti-adrenergic drugs (e.g., beta-blockers, clonidine, guanethidine, and reserpine).

ADVERSE REACTIONS

Other adverse reactions commonly associated with Apidra® include injection site reactions, lipodystrophy, pruritus, and rash.

Important Safety Information for Apidra® (insulin glulisine [rDNA origin] injection) SoloSTAR®

Apidra® SoloSTAR® is a disposable prefilled insulin pen. To help ensure an accurate dose each time, patients should follow the steps in the Instruction Leaflet accompanying the pen; otherwise they may not get the correct amount of insulin, which may affect their blood glucose.

Please click here for Full Prescribing Information for Apidra®.

Click here for information on Sharps Medical Waste Disposal.

Read more...

*Offer is not valid for patients participating in Medicare, Medicaid, or any other federal- or state-funded benefit programs. Void where prohibited by law. Sanofi US reserves the right to rescind, revoke, or amend this program without notice. Maximum offer value $100 per prescription. Offer valid for up to 15 prescriptions/refills through December 31, 2014.

References

  1. Apidra® Prescribing Information. October 2013.
  2. Lankisch MR, Ferlinz KC, Leahy JL, Scherbaum WA; Orals Plus Apidra and Lantus (OPAL) study group. Diabetes Obes Metab. 2008;10(12):1178-1185.
  3. Hancu N, Czupryniak L, Genestin E, Sourji H. J Diabetes Sci Technol. 2011:5(5):1224-1234
Flash Player
Flash Player

You need a Flash Player in order to view some content. You are about to be directed to Macromedia Flash Player Download Center.

Click the CONTINUE button below to go to the Macromedia Flash Player Download Center, or the CANCEL button to return to the previous page.

NOTE: After installation is complete, please restart your browser.

Cancel
Continue
Flash Player